MetaCap

First Tracks Biotherapeutics Inc. (TRAX)

NASDAQ: TRAXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

41.64-2.82 (-6.34%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TRAX stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$4.71
52-week range
14.72 – 54.78
Day range
41.51 – 44.51
Volume / Avg
504.36K / 826.70K
Beta
—

52-week range

$14.72$54.78

TRAX stock today

On Nov 20, TRAX ended the session at $41.64, shedding $2.82 (6.34%), versus the S&P 500's 3.70% decline. Shares are 24.0% below their 52-week high of $54.78, set on Nov 10, 2026 and 182.9% above the 52-week low of $14.72, in the middle of the past year's range. First Tracks Biotherapeutics has posted a net loss over the last twelve months (EPS of -$4.71), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About First Tracks Biotherapeutics

Company profile

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs).

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Daniel R. Faga
Headquarters
San Diego, CA
Employees
104

Analyst forecast

Forecast

Consensus (12 analysts)

strong_buy

Avg. price target

$75.17+80.52%

  • Strong buy 3
  • Buy 9
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $57.00High $110.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.88 vs $-0.92
Surprise
+4.35%

TRAX news

All TRAX news

First Tracks Biotherapeutics peers

Health Care sector
TRAX peer companies
CompanyPrice% ChgMarket capCompare
STOKStoke Therapeutics Inc.26.81-0.45%$1.75Bvs TRAX
ETONEton Pharmaceuticals Inc.60.85-0.83%$1.76Bvs TRAX
SDGRSchrodinger Inc.22.93-12.95%$1.72Bvs TRAX
KRSAKorsana Biosciences Inc.37.56+5.95%$1.71Bvs TRAX
ZYMEZymeworks Inc.26.14-2.68%$1.81Bvs TRAX
MRVIMaravai LifeSciences Holdings Inc. Class A6.98-2.92%$1.81Bvs TRAX
RAREUltragenyx Pharmaceutical Inc.16.48-4.30%$1.68Bvs TRAX
BRVEBraveheart Bio Inc.20.39+5.81%$1.67Bvs TRAX

Indexes, lists and sector

First Tracks Biotherapeutics stock FAQ

What is First Tracks Biotherapeutics's stock price today?

TRAX last traded at $41.64 as of Nov 20, 4:00 PM EST, down 6.34% on the day. Prices are delayed at least 15 minutes.

Who is First Tracks Biotherapeutics's CEO?

Mr. Daniel R. Faga is the chief executive officer of First Tracks Biotherapeutics Inc., which has about 104 employees.

What is the TRAX 52-week high?

The 52-week high for TRAX is $54.78 and the 52-week low is $14.72. The stock is currently 24.0% below its high.

Compare TRAX